PNC Financial Services Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-4,277
| Closed | -$16K | – | 4148 |
|
|
2020
Q1 | $16K | Sell |
4,277
-553
| -11% | -$2.38K | ﹤0.01% | 3239 |
|
|
2019
Q4 | $26K | Buy |
4,830
+2,944
| +156% | +$15.6K | ﹤0.01% | 3229 |
|
|
2019
Q3 | $10K | Sell |
1,886
-2,452
| -57% | -$12.2K | ﹤0.01% | 3573 |
|
|
2019
Q2 | $27K | Buy |
4,338
+581
| +15% | +$2.8K | ﹤0.01% | 3233 |
|
|
2019
Q1 | $18K | Buy |
3,757
+350
| +10% | +$1.58K | ﹤0.01% | 3420 |
|
|
2018
Q4 | $15K | Buy |
3,407
+1,067
| +46% | +$5.43K | ﹤0.01% | 3421 |
|
|
2018
Q3 | $15K | Buy |
2,340
+25
| +1% | +$192 | ﹤0.01% | 3550 |
|
|
2018
Q2 | $19K | Buy |
2,315
+458
| +25% | +$3.5K | ﹤0.01% | 3471 |
|
|
2018
Q1 | $13K | Sell |
1,857
-5
| -0.3% | -$33 | ﹤0.01% | 3624 |
|
|
2017
Q4 | $11K | Buy |
1,862
+1,470
| +375% | +$8.93K | ﹤0.01% | 3664 |
|
|
2017
Q3 | $3K | Sell |
392
-53
| -12% | -$337 | ﹤0.01% | 3974 |
|
|
2017
Q2 | $3K | Buy |
445
+140
| +46% | +$1.03K | ﹤0.01% | 3953 |
|
|
2017
Q1 | $3K | Buy |
+305
| New | +$3.04K | ﹤0.01% | 3895 |
|
|
2016
Q3 | – | Sell |
-562
| Closed | -$2K | – | 4425 |
|
|
2016
Q2 | $2K | Sell |
562
-21
| -4% | -$101 | ﹤0.01% | 4261 |
|
|
2016
Q1 | $3K | Sell |
583
-3,980
| -87% | -$17.7K | ﹤0.01% | 4106 |
|
|
2015
Q4 | $28K | Hold |
4,563
| – | – | ﹤0.01% | 3134 |
|
|
2015
Q3 | $26K | Buy |
4,563
+19
| +0.4% | +$146 | ﹤0.01% | 3235 |
|
|
2015
Q2 | $34K | Buy |
4,544
+233
| +5% | +$1.41K | ﹤0.01% | 3245 |
|
|
2015
Q1 | $26K | Sell |
4,311
-50
| -1% | -$315 | ﹤0.01% | 3383 |
|
|
2014
Q4 | $33K | Sell |
4,361
-100
| -2% | -$598 | ﹤0.01% | 2965 |
|
|
2014
Q3 | $23K | Hold |
4,461
| – | – | ﹤0.01% | 3015 |
|
|
2014
Q2 | $18K | Buy |
4,461
+311
| +7% | +$1.19K | ﹤0.01% | 2968 |
|
|
2014
Q1 | $17K | Sell |
4,150
-100
| -2% | -$511 | ﹤0.01% | 2904 |
|
|
2013
Q4 | $24K | Hold |
4,250
| – | – | ﹤0.01% | 2754 |
|
|
2013
Q3 | $22K | Buy |
4,250
+200
| +5% | +$1.08K | ﹤0.01% | 2808 |
|
|
2013
Q2 | $18K | Buy |
+4,050
| New | +$18.2K | ﹤0.01% | 2796 |
|
Other funds holding PGNX
PNC Financial Services Group's PGNX Position: Q2 2020 in Review
PNC Financial Services Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 4,277 shares — an estimated $16K sold.
PNC Financial Services Group first reported a position in PGNX in Q2 2013 and held it in 26 quarters. The position peaked at $34K in Q2 2015. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- PNC Financial Services Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- PNC Financial Services Group sold 4,277 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $16K.
- PNC Financial Services Group first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 26 quarters.
- PNC Financial Services Group's Progenics Pharmaceuticals Inc position peaked at $34K in Q2 2015.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on PNC Financial Services Group's 13F filing for Q2 2020, filed 7 Aug 2020.